CochLear (OTCMKTS:CHEOY) Hits New 52-Week Low – Should You Sell?

CochLear Ltd. Unsponsored ADR (OTCMKTS:CHEOY)’s stock price reached a new 52-week low on Friday . The company traded as low as $70.31 and last traded at $70.58, with a volume of 880 shares traded. The stock had previously closed at $86.32.

CochLear News Roundup

Here are the key news stories impacting CochLear this week:

• Neutral Sentiment: Transcript of the Q2 FY26 earnings call — management confirmed profit decline, described ongoing price‑rise negotiations with some payors, warned that Nexa launch timing has slipped, and flagged currency headwinds; gives detail investors are pricing in. Cochlear Limited (CHEOY) Q2 2026 Earnings Call Transcript
• Neutral Sentiment: Analyst/review coverage — standalone write‑ups comparing Cochlear with peers and reviewing fundamentals; useful background but not new company-specific catalysts. Reviewing CochLear (OTCMKTS:CHEOY) and CVS Health (NYSE:CVS)
• Negative Sentiment: Half-year profit fell ~21%, management pointed to slow price‑raise negotiations and softer margins — headline earnings weakness cited as the primary earnings shock. Cochlear’s 1H Profit Drops 21% After Price Rise Negotiations — Update
• Negative Sentiment: Shares slid on the HY results and management’s muted guidance for the near term — investor reaction drove significant downside in the stock. Cochlear shares slide on HY earnings drop, muted guidance
• Negative Sentiment: Delays to the Nexa implant program were highlighted as a material operational setback, squeezing near‑term revenue and prompting fears of longer product cadence. Cochlear’s Profit Impacted by Nexa Delays
• Negative Sentiment: Coverage summarizing the broader earnings‑season hit to the stock and investor sentiment; frames Cochlear as among the harder‑hit healthcare names this cycle. Cochlear crashes in latest earnings season carnage
• Negative Sentiment: Management and media highlighted AUD weakness as an earnings headwind; ANZ forecasts an AUD around US$0.73, which would further pressure USD‑reported results if sustained. ANZ says AUD heading for US $0.73 as Cochlear warns of currency impacts
• Negative Sentiment: CEO comments on-camera reiterating that AUD fluctuations are weighing on earnings and margins — amplifies investor concern about currency exposure and near‑term profitability. Cochlear CEO: AUD currency fluctuations weighing on earnings
• Negative Sentiment: Local press reports the share price hit a multi‑year low after the implant delays and results — indicates the market has materially repriced risk around product timing and margin recovery. Cochlear shares hit three-year low on new implant delays

Analysts Set New Price Targets

Separately, Royal Bank Of Canada upgraded CochLear from a “hold” rating to a “moderate buy” rating in a report on Monday, January 19th. Two analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy”.

CochLear Stock Performance

The business’s 50-day simple moving average is $89.15 and its two-hundred day simple moving average is $93.06.

CochLear Company Profile

Cochlear Limited provides implantable hearing solutions for children and adults worldwide. It offers cochlear implant systems, sound processor upgrades, bone conduction systems, accessories, and other products. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.